Skip to Main Content
An official website of the United States government
Login Change: CDAS is now using the NIH Researcher Auth Service (RAS) to manage our existing login options. When logging into CDAS, you will be taken to RAS, where you can select your preferred login provider to access CDAS.

Browse Lab Results > 2006-0279

Trial Summary

About CDAS Project, PI, Publications: Validation of Serum Markers for early Detection of Ovarian Cancer

Datasets

Site: Ovary

Inclusion Criteria:

  • Females
  • No Prior History of Any Cancer
  • No Report of Bilateral Oophorectomy
  • Exclude LMPs and Reported Cancers

Matching Factors:

  • Age at Serum Draw (5 years)
  • Year of Serum Draw

Match Ratio: 4:1 for general controls, 2:1 for controls who ever had an elevated CA-125, and 2:1 for controls who have a family history of breast or ovarian cancer

Match Technique: Frequency matching only non-cases as controls.

Analytes:

  • Apolipoprotein A-I
  • Beta-2-microglobulin
  • Cancer Antigen 125
  • Cancer Antigen 15-3
  • Cancer Antigen 19-9
  • Cancer Antigen 72-4
  • Connective Tissue-Activating Peptide III
  • Eotaxin
  • Epidermal Growth Factor Receptor
  • Hepcidin-25
  • Human Epididymis Protein 4
  • Insulin-like Growth Factor 2
  • Insulin-like Growth Factor Binding Protein 2
  • Inter-alpha-trypsin inhibitor heavy chain H4
  • Kallikrein-6
  • Leptin
  • Macrophage Migration Inhibitory Factor
  • Matrix Metalloproteinase-3
  • Matrix Metalloproteinase-7
  • Mesothelin
  • Osteopontin
  • Prolactin
  • Secretory Leukocyte Protease Inhibitor
  • Soluble Vascular Cell Adhesion Molecule
  • Spondin 2
  • Transferrin
  • Transthyretin
  • V-set domain-containing T-cell activation inhibitor 1

Number of Cases: 119

Number of Controls: 952